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Abstract
The (pro)renin-renin receptor, (P)RR has been claimed to be a novel element of the renin-angiotensin system (RAS). The
function of (P)RR has been widely studied in renal and vascular pathology but the cardio-specific function of (P)RR has not
been studied in detail. We therefore generated a transgenic mouse (Tg) with cardio-restricted (P)RR overexpression driven
by the alpha-MHC promotor. ThemRNA expression of (P)RR was,170-fold higher (P,0.001) and protein expression,5-fold
higher (P,0.001) in hearts of Tg mice as compared to non-transgenic (wild type, Wt) littermates. This level of overexpression
was not associated with spontaneous cardiac morphological or functional abnormalities in Tg mice. To assess whether (P)RR
could play a role in cardiac hypertrophy, we infused ISO for 28 days, but this caused an equal degree of cardiac hypertrophy
and fibrosis in Wt and Tg mice. In addition, ischemia-reperfusion injury was performed in Langendorff perfused isolated
mouse hearts. We did not observe differences in parameters of cardiac function or damage between Wt and Tg mouse
hearts under these conditions. Finally, we explored whether the hypoxia sensing response would be modulated by (P)RR
using HeLa cells with and without (P)RR overexpression. We did not establish any effect of (P)RR on expression of genes
associated with the hypoxic response. These results demonstrate that cardio-specific overexpression of (P)RR does not
provoke phenotypical differences in the heart, and does not affect the hearts’ response to stress and injury. It is concluded
that increased myocardial (P)RR expression is unlikely to have a major role in pathological cardiac remodeling.
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Introduction
The (pro)renin-renin receptor, (P)RR, was discovered and
cloned in 2002 as a novel element of the renin-angiotensin system
(RAS) [1]. Stimulation of (P)RR, via (pro)renin or indirectly, has
been suggested to play a role in organ damage, for instance in
blood vessels and the kidney. (P)RR is expressed in kidney,
specifically in renal mesangial cells, brain, vascular smooth muscle
cells and blood vessels, in macrophages, T cells, granulocytes, and
also, albeit at low levels, in the heart [2]. It has been suggested that
(P)RR confers signals from an activated (tissue) RAS [3–5]. But
(P)RR also has specific other functions in the assembly and
function of vacuolar H+-ATPase (V-ATPase), an ATP-dependent
proton pump which acidifies intracellular compartments [6].
Binding of both renin and its inactive precursor, prorenin, to the
(P)RR exerts effects via angiotensin II-independent pathways,
e.g.via second messengers including mitogen-activated protein
kinases (MAPK) [2]. This has been shown to be associated with
increased cell proliferation and upregulation of profibrotic genes
[7]. Animal studies have suggested that (P)RR overexpression
causes nephropathy and hypertension as well as activation of RAS
[8–10]. It has been suggested that increased expression of (P)RR
may be involved in renal and cardiac pathophysiology [7,11–14].
The pathophysiological role of (P)RR was mainly investigated
based on analyses of an animal model of ubiquitously (P)RR
overexpression [8,9] and a rat model of (P)RR overexpression in
vascular smooth muscle cells, which resulted in elevated blood
pressure and aldosterone levels [15]. In the heart however, the
phenotypic consequences of altered (P)RR signaling are less clear.
Cardiomyocyte-specific deletion of (P)RR causes a fulminant
cardiomyopathy, an effect largely attributable to the impaired
acidification due to the V-ATPase function of (P)RR [6]. We have
shown that (P)RR expression is increased in murine, rat and
human heart failure suggesting that (P)RR may play a role in
cardiac remodeling [11]. A very recent study has indicated that
(P)RR overexpression by adenovirus mediated gene delivery
resulted in enhanced matrix remodeling [16]. Therefore consid-
erable interest exists to study the functional consequences of (P)RR
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expression and activation in the heart as the precise role of (P)RR,
if any, in cardiac disease remains unclear.
In the present study, we investigated the role of (P)RR by
generating a mouse with cardiorestricted (P)RR overexpression,
and evaluated its functional consequences in cardiac remodeling
and dysfunction. Furthermore, we also examined the role of (P)RR
in ischemia-reperfusion injury. We report that cardio-specific
overexpression of (P)RR did not provoke phenotypical differences,
and did not affect the hearts’ response to stress and injury.
Therefore, based on this study, it is suggested that (P)RR has no or
marginal contribution to the cardiac remodeling process.
Materials and Methods
Animal Model and Experimental Protocols
Generation of a transgenic mouse with cardio-restricted
(P)RR overexpression. The murine (P)RR gene (Gene bank:
NM_027439) was amplified by polymerase chain reaction (PCR)
using primers containing SalI and HindIII restriction sites (Table
S1). The PCR product was cloned into a previously described
vector containing the cardio-specific a-MHC promoter [17,18].
The BamHI fragment of this construct, containing a-MHC
promoter and downstream (P)RR cDNA sequence, was subse-
quently used for pronuclear injections to generate a transgenic
mice with cardiorestricted (P)RR overexpression in a FVB
background. After multiple pronuclear injections, we succeeded
to generate one transgenic mouse line; a total of 22 mouse lines
turned out to be non-transgenic. The transgenic mice were
subsequently back-crossed with C57BL/6J mice. Transgenic
offspring were identified by PCR amplification of the transgene.
Male transgenic (Tg) mice were used for all the experiments and
non-transgenic littermates were used as wild type (Wt) controls for
comparison with Tg mice.
Ethics
The protocols describing the animal experiments were ap-
proved by the Animal Ethical Committee of the University of
Groningen, the Netherlands, and conforms with the Guide for the
Care and Use of Laboratory Animals published by the Directive
2010/63/EU of the European Parliament.
Perturbations
Isoproterenol induced cardiac remodeling. Male mice,
aged 8–12 weeks (n = 7) were allocated to two groups, a saline
group and isoproterenol (ISO) group. All solutions were contin-
uously infused for 28 days via osmotic minipumps (Charles River),
as described previously [19]. In order to induce cardiac
hypertrophy, mice were treated with ISO (Sigma Aldrich,
35 mg/kg/d) in saline with 0.1% ascorbic acid. Saline-treated
animals received saline and 0.1% ascorbic acid as control. Briefly,
the minipumps were implanted in the left flank of the mice under
Figure 1. Generation of (P)RR transgenic mice and baseline characteristics. A) Schematic depiction of the generation of Tg mice with
cardiomyocyte-restricted (P)RR overexpression. We cloned the 1060 bp murine (P)RR cDNA in front of the a 5.5-kb a-MHC promoter. B) (P)RR mRNA
expression normalized to 36B4 by RT-PCR of Tg mice and their Wt littermates (left upper panel); western blot for (P)RR and GAPDH protein from
hearts of Tg and Wt mice (bottom panel) and quantification of the western blot (right upper panel). C) Heart-weight (HW) normalized to body weight
(BW) in adult Wt and Tg mice (left upper panel); images for Masson staining for quantification of fibrosis (bar size 100 mm) and haematoxylin and
Eosin staining (bar size 70 mm) for assessment of cardiac morphology (bottom pannels) and quantification of Masson staining (right upper panel). D)
mRNA expression of ANP, BNP, Gal-3, Col-1, Col-3, and MCIP1 (normalized to 36B4) of the Wt and Tg mice. Fold changes are shown. *** P,0.001, Wt vs.
Tg.
doi:10.1371/journal.pone.0089929.g001
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isoflurane (2% in air) anesthesia. At the end of the treatment
animals were sacrificed, hearts were weighed and collected for
molecular analysis.
Langendorff isolated heart perfusion. Experiments were
performed with male mice, aged 8–12 weeks (n = 6). Hearts were
isolated and perfused in the Langendorff mode (60 mmHg, 37uC)
using a commercially available Langendorff set-up (Harvard
Apparatus), as describe previously [20]. Briefly, mice were
anesthetized with isoflurane; heparin (200 IU/Kg) was injected
to prevent coagulation. Hearts were excised and immediately
placed in cold (4uC) Krebs Henseleit bicarbonate buffer solution
(KH, in mM): 118 NaCl, 11 glucose, 4.7 KCl, 24 NaHCO3, 2
CaCl2, 0.1 pyruvate, 0.5 glutamine, 1 lactate and 1.2 MgSO4. The
aorta was rapidly cannulated and the hearts were perfused in a
retrograde mode. The KH buffer was saturated with 95% O2 and
5% CO2 at 37uC providing a pH of 7.4.
A water-filled balloon was inserted through the left atrium into
the left ventricle and adjusted to achieve a left ventricular end-
diastolic pressure (LVDEP) of ,5–10 mmHg, and equilibrated for
15 minutes. Left ventricular developed pressure (LVDP) was
measured with an intraventricular balloon catheter attached to a
computerized bridge amplifier during the entire experiment. After
15 minutes of equilibration, global ischemia was induced by
stopping the flow of KH-buffer over the heart for 45 minutes, and
then the flow was restarted to create 30 minutes of reperfusion.
Heart function was measured at various times points of the
protocol.
Heart functional measurements. The left ventricular
developed pressure (LVDP) and rate pressure product (RPP) were
calculated as LVDP= left ventricular systolic pressure (LVSP) –
left ventricular end diastolic pressure (LVEDP); RPP= (heart rate
(HR)6LVDP).
Echocardiography and Blood Pressure Measurements
Cardiac function was assessed by echocardiography at baseline
and prior to sacrifice with Vivid 7 (GE Healthcare, Chalfont St
Giles, UK) equipped with a 13-MHz (mice) phase array linear
transducer), as described previously [21]. The echocardiographic
measurements were performed under general anesthesia with 2%
isoflurane. Both 2-dimensional (2D) images in parasternal long-
axis and short-axis view and 2-D guided M-mode tracing were
obtained.
Furthermore, prior to sacrifice, blood pressure was measured,
using an indwelling pressure tip catheter (Millar Instruments,
Houston, TX, USA), that is introduced in the right carotid artery
and advanced into the LV as described previously [21]. Blood
pressure was recorded in the aortic arch, proximal to the aortic
constriction.
Masson Trichrome and Hematoxylin Staining
Masson’s trichrome staining was performed on paraffin sections
of hearts from all experimental animals. Whole stained sections
were scanned by a scanning system (ScanScope, Aperio Technol-
ogies, Vista, CA, USA). Total fibrosis was calculated automatically
by the software at a 206magnification for the entire section and
expressed as percentage of total area, as described previously [22].
Paraffin sections were stained with Hematoxylin and Eosin (H&E)
for gross appearance of the hearts and whole stained sections were
scanned by a scanning system (ScanScope, Aperio Technologies,
Vista, CA, USA).
Furthermore, to quantify individual myocyte size, paraffin
sections were stained with isothiocyanate-conjugated wheat germ
agglutinin (FITC-WGA) as described previously [23]. Myocyte
area was assessed 206magnification and analyzed with Image J
software. Average myocyte area was evaluated by measurement of
,400 cells per group of mice.
Western Blot Analysis
A total of 35 mg of whole tissue protein lysates were separated
on a SDS-PAGE gel and proteins were immunoblotted onto
nitrocellulose membranes. Membranes were incubated with goat
polyclonal (P)RR primary antibody (Novus Biological, catalogue#
NB100-1318, 1 mg/mL) or with phospho-ERK mouse monoclonal
antibody (Santa Cruz, catalogue#SC7383, 1:1000 dilution), or
with ERK(1/2) rabbit polyclonal antibody (Cell Signaling,
catalogue#4695, 1:1000) or with phospho-p38 rabbit polyclonal
antibody (Cell Signaling, catalogue#9211, 1:1000) or with p38
rabbit polyclonal antibody (Cell Signaling, catalogue#9212,
1:1000) or with anti-Hsp47 rabbit monoclonal antibody (Abcam,
catalogue#ab109117, 1:1000) or with rabbit monoclonal GAPDH
primary antibody (400 ng/mL, Fitzgerald Inc.). After incubation
with secondary polyclonal rabbit anti-goat (Dako Inc. 1:4000) or
horse anti-mouse (Cell signaling, catalogue#7076, 1:1000) or
polyclonal goat anti-rabbit (1:2000) antibodies, proteins were
detected using Super Signal West Pico Chemiluminescent
Substrate (Thermo Scientific Inc.). The band densities were
scanned and quantified using a Bio Imaging (Syngene, Cam-
bridge, United Kingdom) device and normalized to GAPDH.
Measurement of Lactate Dehydrogenase (LDH) and
Creatine Kinase (CK)
Samples of coronary effluent were collected from isolated
perfused mouse heart at the following time points: 1) the end of a
20 minutes stabilization period, 2) immediately after 45 minutes of
global ischemia, 3) after 5 minutes reperfusion, 4) after 10 minutes
reperfusion, and 5) after 30 minutes reperfusion. After collection,
samples were frozen at 280uC. The LDH (Cayman Chemical
Co.) and CK (Bio Assay Systems) assays were performed using a
spectrophotometer, according to the manufacturers’ protocol.
Cell Culture and Induction of Hypoxia
HeLa S3 cells were cultured in DMEM with 4.5 g/L glucose
supplemented with 10% FCS, 100 U/mL penicillin and 100 mg/
mL streptomycin. Cells were grown in a humidified incubator at
5% CO2 and 37uC. For plasmid transfection of HeLa S3 cells,
lipofectamine LTX reagent (Invitrogen) was used. Cells in a 12-
well plate at 60–80% confluency were transfected with 0.5 mg
DNA for 24 h. For induction of hypoxia, cells were either kept in
an air tight with a pouch (Gaspak, Becton Dickinson) without
oxygen or incubated with hypoxia mimetic deferoxamine
(100 mM, Sigma Aldrich) for 24 hours at 37uC.
mRNA Expression and Quantitative RT-PCR
Relative gene expression in left ventricular tissue of (P)RR, atrial
natriuretic peptide (ANP), brain natriuretic peptide (BNP), galectin-
3 (gal-3), collagen-1 (col-1), collagen-3 (col-3), and monocyte
chemotactic protein-1 (MCIP1), were determined by real time
(RT)-PCR and expressed relative to 36B4, as described previously
[24]. In the cell experiments, adrenomedullin (ADM), vascular
endothelial growth factor (VEGF), c-jun and c-fos gene expression
levels were determined by real time (RT)-PCR and expressed
relative to GAPDH. Values were expressed relative to appropriate
control groups. The primers used for the RT-PCR are listed in
Table S1.
Cardiorestricted Overexpression of the (P)RR
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Statistical Analysis
Data are expressed as means 6 standard errors of the mean
(SEM). Differences between two groups were tested using
Student’s t-test and between multiple groups using ANOVA,
and results were considered statistically significant when P-values
were ,0.05.
Results
Baseline Characteristic of the (P)RR Overexpression
Transgenic Mice
The a-MHC-(P)RR construct is shown in figure 1A and was
used to create the Tg mice. mRNA and protein (P)RR expression
was studied in the whole heart. The mRNA expression of (P)RR was
about 170 fold higher (figure 1B) and protein expression of (P)RR
was 5 fold higher (figure 1B) in hearts of Tg mice, as compared to
non-transgenic (wild type, Wt) littermates. To examine the
potential role of (P)RR in the heart, we analyzed the heart weight
(HW) of these animals at 8-weeks of age and did not observe
differences between Wt and Tg mice, as determined by Masson
Trichrome (fibrosis) and Hematoxylin-Eosin (cell appearance)
staining (figure 1C). No obvious morphological abnormalities were
observed in the hearts from Tg mice (figure 1C). To further study
the effect of (P)RR overexpression on the heart, we analyzed a list
of cardiac genes associated with cardiac hypertrophy and fibrosis,
but did not observe differences between Wt and Tg mice
(figure 1D).
(P)RR Exerts no Effects in ISO-induced Cardiac
Hypertrophy
Since we did not observe a spontaneous phenotype in the (P)RR
Tg mice, we conducted experiments to stress the heart. To assess
whether (P)RR plays a role in cardiac hypertrophy, we infused
ISO in both Tg and Wt mice. ISO in a dose of 35 mg/kg/BW for
28 days resulted in marked cardiac hypertrophy, as determined by
the increase in left-ventricular weight (LV-W) to tibia length (TL),
but no difference was observed between the groups (figure 2A).
The expression of the hypertrophic marker ANP was significantly
increased by ISO in Tg and Wt mice (figure 2B). ISO infusion also
significantly increased the expression of renal renin mRNA in both
Figure 2. Assessment of isoproterenol induced cardiac hypertrophy in (P)RR transgenic mice. A) Left-ventricular weight (LV-W) to tibia
length (TL)in adult Wt and Tg mice subjected to saline or ISO infusion for 28 days (N = 7 mice in each group). B) ANP mRNA expression (normalized to
36B4) in adult Wt and Tg mice subjected to saline or ISO infusion for 28 days (N= 7 mice in each group). C) Renin mRNA expression (normalized to
36B4) in adult Wt and Tg mice subjected to saline or ISO infusion for 28 days (N = 7 mice in each group). D) a-MHC/b-MHC (ratio) mRNA expression
(normalized to 36B4) in adult Wt and Tg mice subjected to saline or ISO infusion for 28 days (N= 7 mice in each group). E and F) Masson’s trichrome
staining (bar size 100 mm) to assess myocardial fibrosis in adult Wt and Tg mice subjected to saline (sham procedure) or ISO infusion for 28 days; E:
quantification, and F: typical examples of Masson’s trichrome staining. G and H) FITC-WGA staining to assess myocyte hypertrophy in adult Wt and Tg
mice subjected to saline (sham procedure) or ISO infusion for 28 days; G: quantification, and H: typical examples of FITC-WGA staining. *P,0.05, **P,
0.01, sham vs. ISO between Wt mice; #P,0.05, ##P,0.01, sham vs. ISO between Tg mice and 1P,0.05, ISO treatment between Wt and Tg mice.
doi:10.1371/journal.pone.0089929.g002
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Tg and Wt groups (figure 2C) with no differences between groups.
No differences were observed for a-MHC/b-MHC ratio between
the groups (figure 2D). Changes in extracellular matrix (ECM)
may affect cardiac function and therefore we performed Masson
staining to quantify the ECM deposition. As shown in figure 2E
and 2F, the ECM deposition was similarly increased in both Wt
and Tg mice treated with ISO without differences between groups.
Myocyte surface area determined by FITC-WGA staining, a
measure of myocyte hypertrophy, was also increased by ISO in
both Tg and Wt mice, but no difference was observed between the
groups (figure 2G and 2H).
To investigate the expression of stress related proteins which
were previously linked to (P)RR signaling, we assessed protein
expression of ERK1/2, p38 and HSP47 by western blot (figure 3A)
in the heart of saline and ISO treated Wt and Tg mice. The ratio
of phospho2/total Erk1/2 was not significantly different between
groups (figure 3B) and the ratio of phospho2/total p38 was
identical for each group (figure 3C). These observations are in line
with the study with Taglieri DM et al. [25]. Furthermore, HSP47
protein expression was significantly higher in Tg mice at baseline
and ISO stimulation did not affect this (figure 3D). These data
suggest that myocardial overexpression of (P)RR does not
influence the stress related proteins ERK1/2 and p38 with or
without ISO treatment, and may influence HSP47 under control
conditions, but not with ISO treatment.
Echocardiography was performed before sacrificing the animals
(data shown in Table S2). Interventricular septum width (IVSd)
and LV Posterior Wall thickness (LVPWd) were both increased in
Wt and Tg mice upon ISO treatment, confirming cardiac
hypertrophy. No substantial functional differences were observed.
Furthermore, blood pressure measurements were performed at
sacrificing the animals (data shown in Table S2). Mean arterial
pressure (MAP) measured in the aortic arch was significantly
higher in the Wt mice at baseline. Systolic blood pressure (SBP),
diastolic blood pressure (DBP) and mean arterial pressure (MAP)
were significantly increased in Tg mice upon ISO treatment. No
substantial differences were observed between ISO treated Wt and
Tg mice.
Cardiomyocyte-restricted (P)RR Overexpression and
Ischemia Reperfusion Injury
Isolated hearts from Wt and Tg mice were subjected to 45
minutes no-flow global ischemia at 37uC. As shown in figure 4A
and 4B, we assessed myocardial damage by lactate dehydrogenase
(LDH) and creatine kinase (CK) in the coronary effluent at
different time points. Immediately after ischemia (0 min reperfu-
sion) both LDH and CK influx were significantly increased
compared to the stabilization period for both Wt and Tg mice; no
differences were observed between the genotypes neither after
ischemia nor during the reperfusion at 5, 10, and 30 minutes
(figure 4A and 4B). The post ischemic recovery of LVDP and post-
ischemic recovery of RPP at 30 minutes reperfusion were also
similar between the genotypes (figure 4C and 4D). These data
Figure 3. Western blot of ERK1/2, p-38 and HSP47. A) Western blot of the expression of ERK1/2, p-38 and HSP47 proteins from hearts of Tg
and Wt mice with and without ISO treatment. B) Quantification of the ratio of phospho2/total Erk1/2 from hearts of Tg and Wt mice with and
without ISO treatment. C) Quantification of the ratio of phospho2/total p-38 from hearts of Tg and Wt mice with and without ISO treatment. D)
Quantification of the HSP47 protein expression from hearts of Tg and Wt mice with and without ISO treatment. * P,0.05, Wt vs. Tg.
doi:10.1371/journal.pone.0089929.g003
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suggest that myocardial overexpression of (P)RR does not protect
nor exacerbate ischemia/reperfusion injury.
In vitro (P)RR Overexpression in HeLa Cells and Hypoxia
Related Gene Response
Transient transfection of HeLa cells with (P)RR plasmid leads to
a ,130 fold upregulation of (P)RR mRNA (Figure S1) and ,5-
fold upregulation of (P)RR protein [11]. To examine if (P)RR
overexpression has effects on hypoxia we evaluated the expression
of genes involved in hypoxia sensing such as ADM, VEGF, and
other immediate early genes (c-jun and c-fos) in response to hypoxia
and the hypoxia mimicking agent deferoxamine (DFO). Real-time
PCR analysis revealed a significant increase in expression of ADM
and VEGF mRNA in both DFO and hypoxia conditions
(compared to normoxia), but there were no differences in this
response between the control HeLa cells and (P)RR overexpress-
ing HeLa cells (figure 5A and 5B). Similarly, c-jun and c-fos mRNA
expression were also increased significantly in DFO and hypoxia
treated HeLa cells, but no differences were observed between the
control HeLa cells and and HeLa cells overexpressing (P)RR
(figure 5C and 5D).
Discussion
We report the generation of a mouse with cardiorestricted
overexpression of the prorenin-renin receptor (P)RR. We demon-
strate that this a-MHC-(P)RR mouse has no spontaneous cardiac
phenotype, and several established perturbations led to an equal
degree of cardiac damage in Tg and Wt mice. We conclude from
our data that increased myocardial levels of (P)RR are unlikely to
be involved in the development of cardiac remodeling and failure.
Since (P)RR was cloned 11 years ago, there have been many
publications on its putative role in cardiovascular and renal
disease. Until (P)RR was discovered, it was believed that
circulating renin and (pro)renin themselves would be unharmful,
as their effects were thought to be conferred via downstream
elements of the RAS, specifically angiotensin II and aldosterone
[26]. However, binding of renin and prorenin to the (P)RR was
shown to exert specific downstream effects in cell culture systems
Figure 4. Assessment of ex vivo ischemia reperfusion injury by Langendorff isolated heart perfusion in (P)RR Tg mice. A) Leakage of
lactate dehydrogenase (LDH) before and after ischemia and 5, 10 and 30 min after reperfusion of Wt and Tg mice. No significant difference was found
between Wt and Tg mice. B) Leakage of creatine kinase (CK) before and after ischemia and 5, 10 and 30 min after reperfusion of Wt and Tg mice. No
significant difference was found between Wt and Tg mice. C) Functional recovery; LV developed pressure (LVDP) for Wt and (P)RR Tg hearts after
30 min of reperfusion. D) Rate–pressure product (RPP) for Wt and (P)RR Tg hearts after 30 min of reperfusion. Values are means 6 SEM; n = 6 per
group.
doi:10.1371/journal.pone.0089929.g004
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that mimic AngII-induced effects [27,28], for example DNA
synthesis, activation of stress-related kinases (MAPK, ERK),
activation of PAI-1 and phosphorylation of heat shock proteins
[2,29,30]. Furthermore, when (pro)renin or renin bind to (P)RR,
renin activity increases, resulting in enhanced signaling of the
‘classical’ RAS route. Thus, high levels of local (P)RR may
theoretically have profound impact on local RAS activity.
Most studies addressing the role of (P)RR have focused on renal
(patho-)physiology and little knowledge exists on the role of (P)RR
in the heart, one of the main target organs of the RAS. Transgenic
rats have been generated with ubiquitous (P)RR overexpression
and it was reported that no cardiac phenotype was present,
although most articles provide very limited data on the cardiac
phenotype [8,9,15]. Even though beneficial effects of handle
region peptide (HRP), a putative (P)RR blocker, have been
reported, the efficacy and specificity of HRP has generated
contradictory results by other studies [31–33] and caused
considerable debate in the literature.
On the other hand, deletion of (P)RR, the gene product of the
Atp6ap2 gene, results in a lethal cardiomyopathy phenotype which
has been attributed to renin- and prorenin-independent vacuolar
H+ATPase and Wnt receptor signaling of this gene [6,34].
Clearly, the (P)RR is not only a receptor for prorenin and renin,
but has other functions as well that are crucial to the organism.
Therefore, it is warranted to answer the question if overexpression
of (P)RR, as observed in cardiac remodeling [11], is causally
involved with this phenotype or rather a consequence of it.
Therefore, in the present study, we have investigated the role of
myocardial (P)RR overexpression in cardiac remodeling in vivo.
Previous studies in which the human (P)RR was overexpressed
in vascular smooth muscle tissue showed that these transgenic rats
developed hypertension, which might be associated with the
development of nephropathy [15]. Another rat strain in which
human (P)RR was overexpressed ubiquitously, showed that these
rats developed proteinuria and slowly progressive nephropathy, in
the absence of changes in RAS activity suggesting a possible role of
(P)RR in kidney disease [9]. Other studies showed that local (P)RR
expression is increased in patients with diabetic nephropathy and
end-stage kidney disease [35] and animal studies demonstrate up-
regulation of renal (P)RR in rat models of hypertension [10],
diabetes [36] and renal injury [37]. Increased myocardial
expression has been described in the failing hearts of various
species and with various etiologies [11] but the precise mechanism
of (P)RR contribution in the exclusively heart has remained
unclear.
We achieved to generate a transgenic mouse line (one positive
founder line out of .22 lines) and this line had a strong
overexpression of (P)RR mRNA (,170 fold), with a more modest
increase in (P)RR protein of ,5 fold, a level comparable to
increases in common murine and rat models of cardiac remodeling
[11]. This level of overexpression was not associated with
spontaneous morphological abnormalities of the heart of Tg mice,
while transcriptional analyses did not suggest activation of genes
typical for cardiac remodeling, such ANP, BNP and fibrotic genes.
ISO infusion, which causes cardiac remodeling via direct effects on
the heart in combination with increased renin levels caused equal
cardiac hypertrophy and fibrosis in Wt and Tg mice. Also, I/R
injury in the isolated heart caused identical injury toWt and Tg
mouse hearts. Finally, we studied HeLa cells with and without
Figure 5. Effect of (P)RR overexpression on stress related gene expression due to hypoxia. Gene expression levels in HeLa cells under
normoxia, DFO (deferoxamine) treatment and hypoxia; HeLa cells without (fine bars) and with (black bars) (P)RR overexpression. A) ADM B) VEGF C) c-
jun D) c-fos (all normalized to GAPDH). *P,0.05, ***P,0.001, normoxia vs. DFO or normoxia vs. hypoxia, under control condition. #P,0.05, ##P,0.01
and ###P,0.001, normoxia vs. DFO or normoxia vs. hypoxia, under (P)RR overexpression.
doi:10.1371/journal.pone.0089929.g005
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(P)RR overexpression and could not establish any effect of (P)RR
on expression of genes associated with the hypoxic response.
A recent study by Moilanen et al. was the first to specifically
address the role of (P)RR in the heart. The authors employed a
intramyocardial adenovirus mediated gene delivery of (P)RR
which resulted in enhanced matrix remodeling, independent of
AngII generation [16]. This was associated with adverse cardiac
remodeling. Clearly, our results are in contrast to the observations
of this study. The differential outcomes may be explained by the
methodology. First, Moilanen et al. used adenoviral mediated
transfection, and they showed high levels of overexpression after 3
days and 1 week (up to 7-fold), that decreased over the course of
weeks. We achieved stable overexpression of about 5-fold,
throughout the entire life span of the mice. Second, their method
delivered (P)RR throughout the entire left ventricle. The authors
showed predominant myocytic expression, however the method of
delivery may have rsulted in delivery to cardiac fibroblasts, not just
myocytes, so that the effects on the extracellular matrix may be
explained. They do not show if (P)RR was expressed by
extracardiac tissue, which could also have played a role. In our
study, we overexpressed (P)RR in cardiomyocytes only which
easily explains, absence of fibrotic effects. The absence of signaling
via (P)RR was paralleled by the observations we made in a cell
system.
As discussed, (P)RR may not be essential for cardiac remodel-
ing, but previous data suggest an important role for the embryonic
development and organogenesis, especially for the heart [6].
Cardiospecific (P)RR knock out animals are not viable. Batenburg
et. al. recently showed that direct interaction between prorenin or
renin with the (P)RR in vivo is very unlikely to occur in non-renin
synthesizing organs [38]. Therefore, phenotypes [9,15] that
develop in (P)RR overexpressing transgenic rats are probably
largely independent from RAS activity, obscuring the true role of
(P)RR in heart. In our studies, we did not assess if renin or
prorenin binds directly to the (P)RR which is a limitation of our
study. Further, our study only addressed short-term functional
effects of (P)RR overexpression; chronic overexpression of the
(P)RR, for instance in aged mice, may be associated with structural
or functional changes in the heart, but were not assessed in these
studies. However, ISO infusion caused an increase of circulating
renin, while the response in cardiac remodeling was completely
comparable between Wt and Tg mice so that differential renin
signaling is improbable. The complete lack of any phenotypic
manifestation of the Tg mouse, also in models that have
established RAS dependency, supports the notion that cardiac
(P)RR has no clear effect on cardiac physiology.
In conclusion, our studies showed that cardio restricted (P)RR
overexpression exerts no deleterious effects on cardiac function, on
the remodeling process in response to b-adrenergic activation, or
on ex vivo ischemia reperfusion injury. Further studies will be
essential to fully understand the role of (P)RR in cardiac
pathophysiology, but from our data it seems unlikely this role is
of major importance.
Supporting Information
Figure S1 (P)RR mRNA expression in HeLa S3. RT-PCR
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